Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical implications of new drugs for lowering plasma cholesterol concentrations.

× No keyword cloud information.

48 in total

1. Cholesterol synthesis inhibitors in hyperlipidaemia.

Authors: M J Mol; P M Stuyt; A F Stalenhoef; A van 't Laar
Journal: Lancet Date: 1988-03-12 Impact factor: 79.321

2. Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia.

Authors: P Weisweiler; P Schwandt
Journal: Lancet Date: 1986-11-22 Impact factor: 79.321

Review 3. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.

Authors: M S Brown; J L Goldstein
Journal: J Clin Invest Date: 1983-09 Impact factor: 14.808

Review 4. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.

Authors: J M Hoeg; H B Brewer
Journal: JAMA Date: 1987-12-25 Impact factor: 56.272

5. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.

Authors:
Journal: JAMA Date: 1986-11-28 Impact factor: 56.272

6. Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.

Authors: A S Pappu; D R Illingworth; S Bacon
Journal: Metabolism Date: 1989-06 Impact factor: 8.694

7. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.

Authors: G L Vega; C East; S M Grundy
Journal: Atherosclerosis Date: 1988-03 Impact factor: 5.162

8. Therapeutic effects of ML-236B in primary hypercholesterolemia.

Authors: A Yamamoto; H Sudo; A Endo
Journal: Atherosclerosis Date: 1980-03 Impact factor: 5.162

9. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514).

Authors: G Yoshino; T Kazumi; M Iwai; M Matsushita; K Matsuba; R Uenoyama; I Iwatani; S Baba
Journal: Atherosclerosis Date: 1989-01 Impact factor: 5.162

10. The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.

Authors: D R Illingworth; D Corbin
Journal: Proc Natl Acad Sci U S A Date: 1985-09 Impact factor: 11.205

6 in total

Review 1. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors: P Chrisp; N J Lewis; R J Milne
Journal: Pharmacoeconomics Date: 1992-02 Impact factor: 4.981

Review 2. Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols.

Authors: M Cziraky
Journal: Pharmacoeconomics Date: 1998 Impact factor: 4.981

Review 3. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors: M Haria; D McTavish
Journal: Drugs Date: 1997-02 Impact factor: 9.546

4. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects.

Authors: A R Miserez; F A Rossi; U Keller
Journal: Eur J Clin Pharmacol Date: 1994 Impact factor: 2.953

Review 5. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors: G L Plosker; D McTavish
Journal: Drugs Date: 1995-08 Impact factor: 9.546

Review 6. Clinical pharmacokinetics of pravastatin.

Authors: J A Quion; P H Jones
Journal: Clin Pharmacokinet Date: 1994-08 Impact factor: 6.447

6 in total